Answers are grounded in this paper and cite their sources.
Chemoresistance remains a major obstacle in the treatment of oral squamous cell carcinoma (OSCC), especially in advanced cases where surgery is not viable. Conventional chemotherapeutics such as doxorubicin (Dox) and paclitaxel (PTX) function primarily through reactive oxygen species (ROS)-induced cytotoxicity. However, the upregulation of antioxidant defenses—particularly glutathione peroxidase 4 (GPX4)—enables cancer cells to neutralize ROS and resist treatment. In this study, we developed gallium-based metal–organic framework (GaMOF) as a multifunctional nanoplatform to overcome OSCC chemoresistance by modulating intracellular redox homeostasis. GaMOF disrupt antioxidant systems and promote ROS accumulation, thereby triggering ferroptosis, an iron-dependent form of programmed cell death associated with lipid peroxidation. When loaded with Dox or PTX, GaMOF not only enhances drug efficacy in resistant OSCC cell lines but also significantly reduce tumor burden in vivo. Mechanistically, GaMOF inhibits GPX4, elevate Fe2 + and ROS levels, deplete glutathione (GSH), and reduce mitochondrial membrane potential, confirming ferroptosis induction. Notably, Chemoresistance cells were more sensitive to GaMOF than parental cells, highlighting GaMOF’s therapeutic specificity. Our findings underscore the potential of GaMOF as redox-responsive carriers capable of reversing chemoresistance via ferroptosis, offering a promising strategy for improving treatment outcomes in OSCC and other drug-resistant cancers.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: